about
Post-transfusion purpura in an African-American man due to human platelet antigen-5b alloantibody: a case report.Differences in Uptake of Risk Reduction Strategies Among Underserved PopulationsGenomic Disparities in Breast Cancer Among Latinas.Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65Pertuzumab for the treatment of breast cancer.Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer.How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.Deleterious BRCA1/2 mutations in an urban population of Black women.Video intervention increases participation of black breast cancer patients in therapeutic trials.Avastin withdrawal symptoms.Racial Disparities in the Molecular Landscape of Cancer.Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.First, do no harm.PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointCDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunitiesObesity in adult lymphoma survivorsA phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignanciesLeft Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
P50
Q33404807-7C3F9153-FD90-4DDC-BA35-D0A0967DCC8BQ36541035-1D2FF0E4-260E-4BBF-9848-49BB14226365Q37509093-A69553DA-3F45-40F0-82A1-595F3710437FQ37731588-C2E92A76-8F32-41DA-8AD6-BB163FB9055EQ38219674-48730238-36ED-455C-968B-0B59ED245715Q38801413-B601A872-99EF-4811-B927-33169103F393Q38850381-78B5A9E0-1762-4692-A2C7-3ECABA55D1A4Q38896955-BE6A9F23-4062-4E7D-A04F-15F43F02D21AQ40124999-9D269B4D-02E0-41DE-BA76-4918A528989AQ40303275-C1E350F9-2D96-4371-8318-15F8044CB370Q41701585-AEB579C3-5A78-4868-85E3-07BE45814A92Q48494322-6095FA78-3C5F-475D-A948-3E94D29EBAE7Q52723102-5C911FD4-555E-4062-8888-EE3E2206CC6DQ53083669-2729761D-29FC-4AE5-9F85-715F66D4C767Q53127820-9715B2ED-A0BA-4331-AF97-D0173A636576Q55716886-09DB5A5B-89C6-44A7-ADB4-E08CF4E8BFC1Q57107795-64BFE7A9-B701-4D7C-9824-B96C6348D5E1Q57111317-0BD9E105-D475-4BC9-9ED7-2D5EFA57A44EQ84881875-364977BC-5F0C-4C76-8A53-D1548E4BC156Q90185137-22A9016A-E1AE-40E4-AB6A-9287E79ECB3CQ90857295-CF5AC529-F8FD-4291-82EA-670075187C8AQ91570323-4227D575-1672-44C6-B364-788C8A2D8E20
P50
description
researcher ORCID ID = 0000-0001-6615-7076
@en
name
Filipa Lynce
@ast
Filipa Lynce
@en
Filipa Lynce
@es
Filipa Lynce
@nl
type
label
Filipa Lynce
@ast
Filipa Lynce
@en
Filipa Lynce
@es
Filipa Lynce
@nl
prefLabel
Filipa Lynce
@ast
Filipa Lynce
@en
Filipa Lynce
@es
Filipa Lynce
@nl
P31
P496
0000-0001-6615-7076